Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Disabling CCR5 Could Be Key to a Cure—but at What Cost?

Interfering with this receptor on immune cells could have harmful health consequences.

Published
25 June 2019
From
Poz
Study Finds Long-Acting HIV Meds Are Acceptable to Many People, but Differences Exist Among Groups

Now that long-acting antiretroviral therapy (LA-ART) is nearly a reality, is it something that people with HIV will prefer over once-daily pills? A study presented during a poster session at the International Conference on HIV Treatment and Prevention Adherence tried to find out whether LA-ART was as acceptable as daily-pill ART among 374 people living with HIV in a clinic in Houston. While they found that overall, LA-ART was acceptable among a majority of people, it wasn't equally acceptable among all groups.

Published
25 June 2019
From
The Body Pro
Major HIV drug calls for vigilance

A study lead by researchers at the Institute of HIV Research, Medical Faculty of UDE and University Hospital Essen, stumbled over a potential toxicity of integrase inhibitors. The researchers found that INSTI had a dramatic effect on activity of immune cells and in particular reduced the activity and function of CD4 T helper cells. This included a reduced proliferation and multiplication of these cells.

Published
24 June 2019
From
University of Duisberg-Essen
Biktarvy Approved to Treat Pediatric Patients With HIV-1

he Food and Drug Administration (FDA) has approved updated labeling for Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide; Gilead) to include treatment of both adult and pediatric patients weighing at least 25kg with HIV-1 who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy. Previously, the combination therapy had only been approved for adults.

Published
20 June 2019
From
Monthly Prescribing Reference
CytoDyn Announces Major Discovery for its Monotherapy Indication

CytoDyn, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today significant progress in securing the therapeutic effect and safety of leronlimab (PRO 140) with the development of an assay that can reliably determine a patient’s CCR5 status.

Published
20 June 2019
From
CytoDyn press release
Efavirenz Dose Reduction Improves Lipid Profile in Adults With HIV-1

The researchers concluded that “a reduced dose of efavirenz (a 400 mg dose is now recommended as an alternative first-line regimen also by [World Health Organization] can lead to a significant decline in total cholesterol and LDL and should be used especially in patients with cardiovascular or metabolic comorbidities.”

Published
19 June 2019
From
Infectious Disease Advisor
Low trust in vaccines 'a global crisis'

Public mistrust of vaccines means the world is taking a step backwards in the fight against deadly yet preventable infectious diseases, warn experts. A Wellcome Trust analysis includes responses from more than 140,000 people in over 140 countries. Eastern Europe was the world region most sceptical of vaccines, with only 50% of people confident vaccines were safe, with Western Europe in second place, at 59%. People in France were also among the most likely to disagree that vaccines were effective, at 19%, and to disagree that vaccines were important for children to have, at 10%. The World Health Organization lists vaccine hesitancy as one of the top 10 threats to global health.

Published
19 June 2019
From
BBC
CytoDyn: Uncovering An Opportunity

CytoDyn is moving their PRO 140 product candidate closer towards an FDA approval in HIV.

Published
12 June 2019
From
Seeking Alpha
Is It Safe to Alter the CCR5 Receptor? And How Will This Influence HIV Cure Studies?

The HIV cure effort suffered a potential setback this week, as researchers reported an association between having two copies of the CCR5-∆32 mutation and shorter survival.

Published
11 June 2019
From
NEJM Journal Watch
UCSF loses contract as Trump administration restricts fetal tissue research

The Trump administration on Wednesday announced major new restrictions in funding of research involving human fetal tissue — a product that many scientists say is irreplaceable in studying certain diseases — in a move that immediately ended a decades-long partnership with UCSF involving HIV research.

Published
07 June 2019
From
San Francisco Chronicle

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.